Live Analyst Rating Changes 23633 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Benjamin Jackson CFA
JEF

Benjamin Jackson CFA

Jefferies
Wall Street Analyst
★★★☆☆
#2032
on 13Foresight · ranked by our own returns
55%
Success Rate
+1.9%
Average Return
12 of 22 calls profitable · -6.6% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 55% of Benjamin Jackson CFA's ratings turned a profit when each position was held for 1 year — averaging +1.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

38 Buy 6 Hold 3 Sell
Benjamin's Stock Coverage 16 ratings · 2026-08-12
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
GMAB
Genmab
 Aug 07, 2026 BUY Buy
+16.4% avg upside
27 analysts
 — +0.5% ·
FR:IPN
Ipsen
 Aug 03, 2026 SELL Hold
-20.6% avg upside
17 analysts
$135.00
16.48% Downside
 -3.2% ·
CH:COPN
COSMO Pharmaceuticals N.V.
 Jul 28, 2026 BUY Strong Buy
+116.8% avg upside
3 analysts
$110.00
78.30% Upside
 -1.1% ·
CH:GALD
Galderma Group AG
 Jul 23, 2026 BUY Strong Buy
+5.2% avg upside
10 analysts
$205.00
13.00% Upside
 +2.6% ·
ZLDPF
Zealand Pharma
 Jul 13, 2026 HOLD Buy
+61.0% avg upside
11 analysts
$49.32
3.79% Upside
 +5.9% ·
GB:0MGB
Genmab A/S
 Jul 08, 2026 BUY Buy
+0.2% avg upside
23 analysts
$2800.00
48.49% Upside
 · ·
GB:0DPB
Bavarian Nordic AS
 May 19, 2026 BUY Strong Buy
+99.4% avg upside
5 analysts
$280.00
60.11% Upside
 · ·
CH:NOVN
Novartis AG
 Feb 04, 2026 HOLD Buy
-11.3% avg upside
32 analysts
$110.00
12.67% Downside
 +8.1% ·
FR:SAN
Sanofi
 Dec 29, 2025 BUY Strong Buy
+30.0% avg upside
30 analysts
$100.00
32.85% Upside
 -5.5% ·
CH:ROP
Roche Holding AG
 Oct 27, 2025 SELL Buy
-8.6% avg upside
23 analysts
$230.00
37.37% Downside
 -44.0% ·
GB:0QIU
Novo Nordisk
 Oct 27, 2025 SELL Hold
+33.5% avg upside
29 analysts
$290.00
1.23% Downside
 · ·
GB:GSK
GlaxoSmithKline
 Jul 30, 2025 HOLD Hold
+2.1% avg upside
25 analysts
$1450.00
26.05% Downside
 +36.3% ·
GB:AZN
AstraZeneca
 Jul 29, 2025 HOLD Strong Buy
+23.4% avg upside
26 analysts
$10900.00
8.43% Downside
 +10.7% ·
AKBLF
ALK-abello
 Jan 31, 2025 BUY Strong Buy
-0.1% avg upside
2 analysts
$28.51
24.70% Downside
 +77.8% ·
DE:EVT
Evotec
 Nov 13, 2024 HOLD Buy
+352.7% avg upside
8 analysts
$6.80
96.28% Upside
 -38.7% ·
EVO
Evotec AG
 Oct 07, 2024 HOLD Buy
+303.4% avg upside
9 analysts
$3.80
92.48% Upside
 +17.4% ·
🔒 11 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Benjamin Jackson CFA — Frequently Asked Questions
How accurate are Benjamin Jackson CFA's stock ratings?
Based on the calls 13Foresight could measure, about 50% of Benjamin's ratings were profitable over a one-year hold, with an average return of +1.9% per rating, or -6.6% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Benjamin ranked on 13Foresight?
Benjamin Jackson CFA is currently ranked #2032 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Benjamin cover?
Benjamin most recently has ratings on GMAB, FR:IPN, CH:COPN, CH:GALD, ZLDPF, GB:0MGB, GB:0DPB, CH:NOVN, FR:SAN, CH:ROP, GB:0QIU, GB:GSK and 4 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.